Literature DB >> 16317297

Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.

Jane Choi1, Kevin Kong, Tahseen Mozaffar, Randall F Holcombe.   

Abstract

Oxaliplatin-containing chemotherapy regimens are utilized commonly for metastatic colorectal cancer and increasingly in the adjuvant setting following surgical resection. The dose-limiting toxicity is neurotoxicity. Acute neurotoxicity is cold induced and transient. Chronic neurotoxicity usually has a predictable clinical course. It is manifested by paresthesias and dysesthesias of gradually prolonged duration that occur between treatment cycles, and increase in intensity and duration with the cumulative dose. We report here a case of a patient who developed significant grade 3 chronic neuropathy following completion of 6 months of adjuvant oxaliplatin-containing chemotherapy for stage III colon cancer. The neurotoxicity was not preceded by any transient symptoms characteristic of chronic oxaliplatin neuropathy and its onset was unpredictable. Delayed neurotoxicity is a complication which must be considered for patients receiving adjuvant therapy and attempts to utilize the minimum effective cumulative dose of oxaliplatin are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16317297     DOI: 10.1097/01.cad.0000185185.64980.70

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.

Authors:  Naohiko Inoue; Hideyuki Ishida; Motohiko Sano; Tohru Kishino; Norimichi Okada; Kensuke Kumamoto; Keiichiro Ishibashi
Journal:  Int J Clin Oncol       Date:  2011-08-11       Impact factor: 3.402

2.  Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.

Authors:  Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh
Journal:  Support Care Cancer       Date:  2013-08-01       Impact factor: 3.603

3.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Authors:  Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

4.  Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy.

Authors:  Dawn Hershman; Elizabeth Calhoun; Kinga Zapert; Shawn Wade; Jennifer Malin; Rich Barron
Journal:  Arch Drug Inf       Date:  2008-09

5.  Oral administration of Cystine and Theanine ameliorates oxaliplatin-induced chronic peripheral neuropathy in rodents.

Authors:  Takehiro Kawashiri; Daisuke Kobayashi; Nobuaki Egashira; Takashi Tsuchiya; Takao Shimazoe
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

6.  Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy.

Authors:  Yeongcheol Cheong; Hidetoshi Katsuno; Hiroshi Matsuoka; Masahiro Mizuno; Tomoyoshi Endo; Tadahiro Kamiya; Yosuke Tajima; Keigo Ashida; Yoshikazu Koide; Koji Masumori; Harunobu Sato; Tsunekazu Hanai; Kotaro Maeda; Ichiro Uyama; Junichiro Hiro; Koichi Suda
Journal:  Fujita Med J       Date:  2021-11-25

7.  Self-management of oxaliplatin-related peripheral neuropathy in colorectal cancer survivors.

Authors:  Cindy Tofthagen; Laura Gonzalez; Constance Visovsky; Alex Akers
Journal:  Chemother Res Pract       Date:  2013-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.